血清中miR-29a和miR-92a在结直肠癌诊断和预后判断中的价值  

The value of diagnosis and prognosis prediction of serum miR-29a and miR-92a for colorectal cancer

作　　者：奉林 庞智[2] 沙莎[3] 吴兵[3] 徐峰[2] 尹少朋[2] 

机构地区：[1]苏州市立医院北区肿瘤内科 [2]苏州市立医院北区消化内科,苏州215008 [3]苏州市吴中人民医院消化内科,苏州215000

出　　处：《中国肿瘤临床与康复》2013年第12期1313-1315,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨血清微小RNA(miR-29a和miR-92a)在结直肠癌(CRC)诊断和预后判断中的价值。方法选取无转移的结直肠癌患者50例和存在肝转移的患者48例,同时募集50名健康志愿者为对照组,按类似的年龄和性别相匹配的队列组合。应用实时荧光定量聚合酶链反应(PCR)法检测微小RNA(miR-29a和miR-92a)水平,判断该血清微小RNA在结直肠癌早期诊断和预后判断中的价值。结果结直肠癌患者血清中miR-29a和miR-92a水平均显著高于健康对照者(P<0.01);血清miR-29a和miR-92a分别进行结直肠癌诊断时的灵敏度为71.4%和75.3%,特异度为84.0%和88.3%;结直肠癌肝转移患者血清中miR-29a和miR-92a水平均显著高于未转移的CRC患者(P<0.05);miR-29a和miR-92a分别鉴别转移性与非转移性CRC患者的敏感性为79.4%和78.6%,特异性为85.3%和86.6%。结论 miR-29a和miR-92a可能是新的非侵入性指标用于结直肠癌患者的早期诊断,血清中miR-29a和miR-92a水平升高与结直肠癌患者预后有关,miR-29a和miR-92a有望成为结直肠癌筛查和早期诊断和预后判断的指标。Objective The purpose of this study was to investigate the value of diagnosis and prognosis prediction of serum miR-29a and miR-92a for colorectal cancer. Methods Serum miR-29a and miR92a were detected by using real-time RT-PCR,corresponding 50 CRC patients without metastasis,48 CRC patients with liver metastasis and 50 healthy volunteers. They were a similar cohort of ageand sex-matched CRC patients without and with metastasis. The value of diagnosis and prognosis prediction of serum-specific miR-29a and miR-92a for CRC was evaluated. Results Serum miR-29a and miR-92a were both significantly higher in CRC patients than in controls（ P〈0. 01）. The sensitivity of miR-29a was 71. 4% and the specificity was 84. 0% in discriminating CRC patients from health controls. The sensitivity of miR-92a was 75. 3% and the specificity was 88. 3%. In addition,increased levels of miR-29a and miR-92a expression were also observed in colorectal tumors from colorectal liver metastasis patients compared with CRC patients（ P〈0. 05）. The sensitivity of miR-29a was 79. 4% and the specificity was 85. 3% in discriminating metastatic from non-metastatic patients. The sensitivity of miR-92a was 78. 6% and the specificity was 86. 6%. Conclusions These findings suggest that serum miR-29a and miR-92a have strong potential as novel noninvasive biomarkers for early diagnosis of CRC patients and high levels of serum miR-29a and miR-92a were associated with poor prognosis. It may represent novel and sensitive noninvasive biomarkers in early diagnosis and prognosis prediction of colon cancer.

关 键 词：结直肠肿瘤 血清 微小RNA 生物学标记 诊断 

分 类 号：R735.3[医药卫生—肿瘤]